Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1998-05-28
2000-01-11
Fonda, Kathleen K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 53, 514 54, 514 61, 424499, A61K 3170
Patent
active
060136359
ABSTRACT:
This invention relates to prevention and/or treatment of antibiotic associated diarrhea, including Clostridium difficile associated diarrhea (CDAD), pseudomembranous colitis (PMC) and other conditions associated with C. difficile infection, using oligosaccharide compositions which bind C. difficile toxin B. More specifically, the invention concerns neutralization of C. difficile toxin B associated with such conditions.
REFERENCES:
patent: 4137401 (1979-01-01), Lemieux et al.
patent: 4238473 (1980-12-01), Lemieux et al.
patent: 4362720 (1982-12-01), Lemieux et al.
patent: 5079353 (1992-01-01), Ratcliffe et al.
patent: 5484773 (1996-01-01), Heerze et al.
patent: 5635606 (1997-06-01), Heerze et al.
patent: 5637576 (1997-06-01), Heerze et al.
patent: 5767093 (1998-06-01), Good et al.
patent: 5817633 (1998-10-01), Heerze et al.
Garegg, P.J., et al., "A Synthesis of 8-Methoxycarbonyloct-1-yl O-.alpha.-D-Galactopyranosyl-(1 .fwdarw. 3)-O-.beta.-D-Galactopyranosyl-(1 .fwdarw. 4)-2-Acetamido-2-Deoxy-.beta.-D-Glucopyranoside", Carbohy Res, 136:207-213 (1985).
Garegg, P. J., et al., "Synthesis of 6- and 6'-deoxy derivatives of methyl 4-O-.alpha.-D-galactopyranosyl-.beta.-D-galactopyranoside for studies of inhibition of pyelonephritogenic fimbriated E. coli adhesion to urinary epithelium-cell surfaces", Carbohy Res, 137:270-275 (1985).
Heerze, L.D., et al., "Oligosaccharide sequences attached to an inert support (SYNSORB) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis," J Infect Dis, 169:1291-1296 (1994).
Jacquinet, J.C., et al., "Synthesis of Blood-group Substances, Part 11. Synthesis of the Trisaccharide O-.alpha.-D-Galactopyranosyl-(1 .fwdarw. 3)-O-.beta.-D-galactopyranosyl-(1 .fwdarw. 4)-2-acetamido-2-deoxy-D-glucopyranose", J C S Perkin, I:326-330 (1981).
Kameyama, A., et al., "Total synthesis of sialyl Lewis X", Carbohy Res, 209:c1-c4 (1991).
Kamiya, S., et al., "Analysis of purity of Clostridium difficile toxin A derived by affinity chromatography on immobilized bovine thyroglobulin", FEMS Microb Lett, 56:331-6 (1988).
Keighley, M.R.B., "Antibiotic-associated pseudomembranous colitis: pathogenesis and management", Drugs, 20:449-56 (1980).
Koike, K., et al., "Total Synthesis of Globotriaosyl-E and Z-Ceramides and Isoglobotriaosyl-E-Ceramide," Carbohy Res, 163:189-208 (1987).
Krivan, H.C., et al., "Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence .alpha.Gal(1-3).beta.Gal(1-4).beta.GlcNAc", Infect Immun, 53:573-81 (Sep. 1986).
Krivan, H.C., et al., "Purification of Clostridium difficile toxin A by affinity chromatography on immobilized bovine thyroglobulin", Infect Immun, 55:1873-7 (Aug. 1987).
Lee, R.T., et al., "Synthesis of 3-(2-Aminoethylthio) PropylGlycosides", Carbohy Res, 37: 193-201 (1974).
Lemieux, R.U., et al., "The properties of a `synthetic` antigen related to the blood-group Lewis A", J Am Chem Soc, 97:4076-83 (Jul. 1975).
Lima, A.A., et al., "Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro," Infect Immun, 56:582-588 (Mar. 1988).
Lyerly, D.M., et al., "Effects of Clostridium difficile toxins given intragastrically to animals," Infect Immun, 47:349-352 (Feb. 1985).
Lyerly D.M., et al., "Clostridium difficile: Its disease and toxins", Clin Microb Rev, 1:1-18 (Jan. 1988).
Lyerly, D.M., "Epidemiology of Clostridium difficile disease", Clin Microb News, 15:49-53 (Apr. 1993).
Okamoto, K., et al., "Glycosidation of Sialic Acid," Tetrahedron, 47: 5835-5857 (1990).
Onderdonk, A.B., et al., "Comparative effects of clindamycin and clindamycin metabolites in the hamster model for antibiotic-associated colitis", J Antimicrob Chem, 8:383-93 (1981).
Paulsen, "Advances in Selective Chemical Syntheses of Complex Oligosaccharide", Angew Chem Int Ed Eng, 21:155-173 (Mar. 1982).
Paulsen, H., "Synthese von oligosaccharid-determinanten mit amid-spacer vom typ des T-antigens", Carbohy Res, 104:195-219 (1982).
Rana, S.S., et al., "Synthesis of Phenyl 2-Acetamido-2-Deoxy-3-O-.alpha. L-Fucopyranosyl-.beta.-D-Glucopyranoside and Related Compounds", Carbohy Res, 91:149-157 (1981).
Riegler, M., et al., J Clin Invest, 95:2004-2011 (May 1995).
Rolfe, R.D., "Binding kinetics of Clostridium difficile toxin A and B to intestinal brush membranes from infant and adult hamsters," Infect Immun, 59:1223-1230 (Apr. 1991).
Schaubach, R., et al., Tumor-Associated Antigen Synthesis: Synthesis of the Gal-.alpha.-3)-Gal-.beta.-(1 .fwdarw. 4)-GICNAc Epitope. A specific Determinant for Metastatic Progression? Liebigs Ann Chem, 607-614 (1991).
Schmidt, "New Methods for the Synthesis of Glycosides and Oligosaccharide--Are There Alternatives to the Koenigs-Knorr Method?" Angew Chem Int Ed Eng, 25:212-235 (1986).
Smith, D.J., et al., "Purification and antigenicity of a novel glucan-binding protein of Streptococcus mutans," Infect Immun, 62:2545-2552, (Jun. 1994).
Sullivan, N.M., et al., "Purification and characterization of toxin A and B from Clostridium difficile", Infect Immun, 35:1032-40 (Mar. 1982).
Tedesco, F.J. "Pseudomembranous colitis: Pathogenesis and therapy", Med Clin No Am, 66:655-64 (May 1982).
Torres, J., et al., "Enterotoxins from Clostridium difficile; diarrhoeogenic potency and morphological effects in the rat intestine," Gut, 31:781-785 (1990).
Triadafilopoulos, G., et al., "Differential effects of Clostridium difficile toxins A and B on rabbit ileum," Gastroent, 93:273-279 (1987).
Tucker, K.D., et al., "Toxin A of Clostridium difficile binds to carbohydrate antigens I, X, and Y", Infect Immun, 59:73-8 (1991).
Von Eichel-Streiber, C., et al., "Clostridium difficile toxin A carries a c-terminal repetitive structure homologous to the carbohydrate binding region of streptococcal glycosyltransferases", Gene , 96:107-13 (1990).
Von Eichel-Streiber, C., et al., "Comparative sequence analysis of the Clostridium difficile toxins A and B", Mol Gen Genet, 233:260-268 (1992).
Wren, B.W., et al., "Antigenic cross-reactivity and functional inhibition by antibodies to Clostridium difficile toxin A, Streptococcus mutans glucan-binding protein, and a synthetic peptide", Infect Immun, 59:3151-5 (Sep. 1991).
Wren, B.W., "A family of clostridial and streptococcal ligand-binding proteins with conserved C-terminal repeat sequences", Mol Microb, 5:797-803 (1991).
Abbas, S.A., et al., "Tumor-Associated Oligosaccharide I: Synthesis of Sialyl-Lewis.sup.a Antigenic Determinant", Sialic Acids, Proc Japan-German Symp, Berlin, 22-23 (1988).
Amvam-Zollo, P., et al., "Streptococcus pneumoniae Type XIV Polysaccharide: Synthesis of a Repeating Branched Tetrasaccharide with Dioxa-Type Spacer-Arms", Carbohy Res, 150:199-212 (1986).
Armstrong, G.D., et al., "Investigation of shiga-like toxin binding to chemically synthesized oligosaccharide sequences", J Infect Dis, 164:1160-7 (1991).
Barbut, F., et al., "Comparison of Enterotoxin Production, cytotoxin production, serogrouping and antimicrobial susceptibilities of clostridium difficile strains isolated from AIDS and human immunodeficiency virus-negative patients", J Clin Microb, 31:740-2 (Mar. 1993).
Bartlett, J.D., "Treatment of antibiotic-associated pseudomembranous colitis", Rev Infect Dis, 6(Suppl 1):S235-41 (Mar.-Apr. 1984).
Bartlett, J.G., et al., "Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia", N Engl J Med, 298:531-534 (1978).
Bartlett, J.G., "Clostridium difficile: History of its role as an enteric pathogen and the current state of knowledge about the organism", Clin Infec Dis, 18(Suppl 4):S265-272 (1994).
Bartlett, J.G., et al., "Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis", Gastroent, 78:431-4 (1980).
Chang, T.W., et al., "Inhibition of binding of Clostridium difficile toxin by steroids", J Infect Dis, 142:113 (1980).
Chernyak, A.Y., et al., "A New Type of Carbohydrate-Containing Synthetic Antigen: Synthesis of Carbohydrate-Containing Polyacrylamide Copolymers having the Specificity of 0:3 and 0:4 Factors of
Armstrong Glen D.
Heerze Louis D.
Fonda Kathleen K.
Synsorb Biotech Inc.
LandOfFree
Treatment of C. difficile toxin B associated conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of C. difficile toxin B associated conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of C. difficile toxin B associated conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1462456